Altman Peter purchased $5K of BCDA

Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.93 on 2026-08-17.

Original reporting
SEC EDGAR · Altman Peter
Published Aug 18, 2026, 4:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 4:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The newest fact is the CEO’s open-market purchase details (5,400 shares at $0.93) and the absence of a pre-arranged 10b5-1 plan, which can slightly increase perceived conviction but does not change fundamentals by itself.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no guidance, trial, deal, or regulatory catalyst in the text.

03

What to watch

The article provides no context on prior insider activity, total insider ownership changes over time, or whether the purchase size is meaningful versus typical CEO buying patterns.

Relevance 4/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDANeutralLow confidence
Context

BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,400 shares at $0.93 on 2026-08-17.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless followed by larger actions or company catalysts.

Evidence & confidence

The filing is a routine insider open-market purchase with no 10b5-1 plan and no accompanying operational or financial disclosure in the text.

Market effects

No sector-level implications from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider open-market buys are often discretionary and can be driven by liquidity needs or diversification rather than a strong forward-looking view.

Key entities

  • BioCardia, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Altman Peter

    President and CEO who reported the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.